LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $100.86M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.62M
Average 0.89M
LENZ Net Income
Bottom-line profit, the starting point for calculating cash from operations.
LENZ Therapeutics, Inc.NASDAQ: LENZ
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $41.49M (cash outflow) rose 183.8% year over year, ahead of the +128.3% change in trailing-twelve-month net income. Sequentially, it rose 15.6% from the prior quarter. Over 3 fiscal years it compounded at -6.7% a year.
Context
- Net income amounted to 430.3% of revenue in FY2025.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$116.31M (+41.6%) for the fiscal year ending Dec 2026, a slowdown from the +65.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$41.49M+15.6% QoQ
- Last fiscal yearDec 2025
- -$82.13M+65.0% YoY
- LTMMar 2026
- -$109M+128.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +183.8% | +121.3% | -62.5 pp |
| 1 year | +65.0% | +41.6% | -23.4 pp |
| 3-year CAGR | -6.7% | -42.3% | -35.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (82.13M) USD
- Year-over-year change
- -65.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (82.13M) | -65.0% |
| FY2024 | 2024-12-31 | (49.77M) | +28.9% |
| FY2023 | 2023-12-31 | (69.97M) | +30.8% |
| FY2022 | 2022-12-31 | (101.05M) | -42.8% |
| FY2021 | 2021-12-31 | (70.76M) | — |
Net Income vs competitors
How LENZ compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +128.3% is the 3rd highest of 11, against a peer median of +19.2%.
- Net income amounts to 519.3% of revenue for LENZ, versus a peer median of 82.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $198.37M USD | -1.8% | +18.2% | 4917.6% | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $197.98M USD | +1165.0% | +70.3% | 200.0% |
| LTM Mar 2026 | $160.72M USD | +309.9% | -21.6% | 84.0% | |
| LTM Mar 2026 | $131.11M USD | +36.0% | +29.4% | — | |
| LTM Mar 2026 | $129.48M USD | +26.7% | +46.0% | — | |
| LTM Mar 2026 | $109M USD | +128.3% | -6.7% | 519.3% | |
| LTM Jun 2026 | $93.67M USD | -68.6% | — | 44.9% | |
| LTM Mar 2026 | $81.49M USD | +11.6% | +21.9% | — | |
| LTM Mar 2026 | $67.31M USD | -51.6% | -15.4% | 34.3% | |
| LTM Mar 2026 | $56.41M USD | +34.0% | +29.0% | — | |
| FY2025 | €23.96M EUR | -64.8% | -25.1% | 80.8% | |
| Peer median (excluding LENZ) | — | +19.2% | +21.9% | 82.4% | |
Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (70.76M) | (101.05M) | (69.97M) | (49.77M) | (82.13M) |
| Depreciation & Amortization | 734K | 8.35M | 15K | 58K | (3.12M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 1.34M | 6.37M | 12.55M |
| Change in Working Capital | (2.5M) | (7.21M) | 9.41M | (13.09M) | 3.25M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (329K) |
| Inventory | 0 | 0 | 0 | 0 | (4.28M) |
| Accounts Payables | 1.83M | 194K | 856K | (4.28M) | (90K) |
| Other Working Capital | (4.32M) | (7.4M) | 8.55M | (8.81M) | 7.95M |
| Other Non-Cash Items | 19.67M | 11.93M | (1.18M) | (2.95M) | 279K |
| Operating Cash Flow | (52.85M) | (87.98M) | (60.38M) | (59.39M) | (69.17M) |
| Capital Expenditures | (5.74M) | (6.59M) | (30K) | (468K) | (827K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (405.52M) | (52.09M) | (241.91M) | (280.8M) |
| Sales of Investments | 0 | 170.25M | 22.5M | 87.9M | 205.96M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (5.74M) | (241.86M) | (29.62M) | (154.48M) | (75.67M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 417.16M | 676K | 203K | 79.51M | 149.75M |
| Common Stock Repurchased | 0 | (79K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 306K | 0 | (2.48M) | 119.49M | 0 |
| Financing Cash Flow | 417.47M | 597K | 80.7M | 199M | 149.75M |
| Effect of Forex Changes | (1.72M) | 0 | 0 | 0 | 0 |
| Net Change in Cash | 357.16M | (329.25M) | (9.3M) | (14.87M) | 4.91M |
| Free Cash Flow | (58.59M) | (94.57M) | (60.41M) | (59.86M) | (70M) |
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.